Radiologists from across Canada descended on Parliament Hill in Ottawa earlier this month to voice pressing concerns on behalf of medical-imaging patients and professionals.

The regions that displayed the most significant differentiations in susceptibility values are known to be associated with neurological conditions such as fatigue, insomnia, anxiety, depression, headaches and other cognitive issues—all common complaints among many COVID long haulers. 

These devices have been tested with lower MRI fields, like 1.5T and 3T, but less is known about their compatibility with more powerful 7T equipment. 

The findings were also found to be associated with the severity of symptoms in individuals with ASD.

Researchers recently presented a new method that considers how already existing lesions grow over time as an indicator of disease progression.

Vessel wall imaging—an MRI technique that offers high resolution images of the vessel wall—may hold clues as to the mechanisms by which COVID infections continue to cause neurologic symptoms after initial recovery in some patients.  

Lyme disease patients treated for “brain fog” may develop compensatory alterations in white matter that show up on MRI and correspond—unexpectedly—with slow but sound cognitive performance.

In the case of a convicted murderer, a New York neuro specialist cited a slew of neuroimaging findings that indicate “severe dysfunction” that could have numbed the defendant’s “brakes of inhibition.”